Loading
For people at very high cancer risk, install a small population of engineered immune cells that live for years and destroy cells showing early cancer signals before a tumour forms.
Immune surveillance normally eliminates most incipient tumours; carriers of BRCA, Lynch or TP53 mutations and people with clonal haematopoiesis face lifelong high risk. Advances in memory stem T cell engineering, logic-gated receptors responsive to stress ligands or shared neoantigens, and safety switches make a persistent, low-level engineered surveillance population conceivable. The proposal is a research programme to define target ligands of pre-malignant cells, engineer persistent gated cells with off-switches, and demonstrate prevention in genetically engineered mouse models before first-in-human studies in the highest-risk carriers.
Shares Vogelstein, Lane and Levine 2000: surfing the p53 network, Inherited risk is mostly unidentified, TP53.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
Shares Vogelstein, Lane and Levine 2000: surfing the p53 network, TP53.
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), TP53.
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.